ACW Stock Overview
A biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Actinogen Medical Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.025 |
| 52 Week High | AU$0.099 |
| 52 Week Low | AU$0.02 |
| Beta | 1.23 |
| 11 Month Change | -7.41% |
| 3 Month Change | 4.17% |
| 1 Year Change | 8.70% |
| 33 Year Change | -82.14% |
| 5 Year Change | -41.86% |
| Change since IPO | -51.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| ACW | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 4.2% | -3.8% | 0.9% |
| 1Y | 8.7% | 9.9% | 17.7% |
Return vs Industry: ACW underperformed the Australian Biotechs industry which returned 10% over the past year.
Return vs Market: ACW underperformed the Australian Market which returned 17.2% over the past year.
Price Volatility
| ACW volatility | |
|---|---|
| ACW Average Weekly Movement | 26.8% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 17.2% |
| 10% least volatile stocks in AU Market | 3.3% |
Stable Share Price: ACW's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: ACW's weekly volatility has increased from 21% to 27% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | Steve Gourlay | actinogen.com.au |
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials, that achieves target engagement in the brain for the treatment of Alzheimer’s disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015.
Actinogen Medical Limited Fundamentals Summary
| ACW fundamental statistics | |
|---|---|
| Market cap | AU$70.68m |
| Earnings (TTM) | -AU$13.04m |
| Revenue (TTM) | AU$9.93m |
7.1x
P/S Ratio-5.4x
P/E RatioIs ACW overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACW income statement (TTM) | |
|---|---|
| Revenue | AU$9.93m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$9.93m |
| Other Expenses | AU$22.98m |
| Earnings | -AU$13.04m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0044 |
| Gross Margin | 100.00% |
| Net Profit Margin | -131.34% |
| Debt/Equity Ratio | 0% |
How did ACW perform over the long term?
See historical performance and comparison